• Mon - Fri : 9.00 - 6.00 EST

Tapentadol faces a consumption boost with the rise in chronic conditions worldwide

Chronic conditions are becoming more common, resulting in a rise in chronic musculoskeletal pain, which is expected to drive up demand for Tapentadol globally. Tapentadol is also used to relieve acute pain that ranges from mild to extreme. This medication is somewhere between morphine and tramadol in terms of efficacy. Its analgesic effect is similar to oxycodone, despite the reduced incidence of side effects. Since there hasn’t been a well-controlled trial for children, the medication is also only provided to adults. The Tapentadol global market is also benefiting from the increasing prevalence of diabetes.

Tapentadol Global Market

Tapentadol has a dual analgesic mode of action that acts as an inhibitor for norepinephrine and an antagonist for mu-opioid receivers. Tapentadol uses include treatment of mild to extreme musculoskeletal pain, classified under chronic or acute conditions. Within minutes of Tapentadol oral administration, the analgesic properties come into force.

On the World Health Organisation (WHO) pain ladder, Tapentadol has been recognized as phase three analgesics. In the United States, it is available in extended releases to form under the brand name Nucynta ER. The extended-release form is used against long-term chronic pain for people seeking 24 hours pain relief support.

Tapentadol Specifications

Tapentadol is also used to relieve discomfort that most forms of analgesics cannot handle. Tapentadol is available in the following strengths of 100 mg (red/orange), 75 mg (orange), or 50 mg (yellow) pills for pain relief and can be taken once every 5 hours. Tapentadol can also be used to monitor diabetic neuropathy pain if analgesics are needed around the clock.

However, the side effects of Tapentadol are considered to be detrimental. It can adversely affect cognitive and physical ability and should not be used for heavy machinery, particularly during first use. Tapentadol has typical side effects such as dizziness, nausea, constipation, and central nervous system (CNS). It will increase the risk of epilepsy and should be used with great caution in epileptic patients.

Key Players and Competitive Landscape

Well-known pharmaceutical firms with well-established trademarks dominate the Tapentadol industry. These companies are striving hard to produce new grades of Tapentadol by investing in their research and development sector. To stay competitive in the industry and expand their reach in the Asia Pacific and Latin America these reputed pharmaceutical companies are now making strategic acquisitions and mergers.

Here are some of the major players in the global Tapentadol industry:-

  • IPCA Laboratories Ltd
  • Ranbaxy Laboratories Ltd
  • Cadila Pharmaceuticals Ltd
  • Johnson & Johnson Pharmaceutical Research & Development
  • Lupin Laboratories Ltd
  • Manus Aktteva Biopharma LLP
  • Aristo Pharmaceuticals Pvt. Ltd
  • IPCA Laboratories Ltd
  • Tirupati Medicare Ltd


Q1. What are the key factors driving the Tapentadol global market?

Answer:- The rising incidence of chronic disorders is contributing to a rise in the frequency of chronic musculoskeletal pain, which is likely to push demand for Tapentadol upward.

Q2. Who are the industry’s most important players?

Answer:-  Taj Pharmaceuticals Limited and Suzhou Shang Enda Biotechnology Ltd are two major players in the Tapentadol industry.

Q3. Which area would have the most influence in the Tapentadol industry?

Answer:-  In terms of sales, North America leads the Tapentadol industry, which is followed by Europe and the Asia Pacific.

Leave a Reply

Your email address will not be published.